Investment Rating - The investment rating for the company is "Buy" for both A and H shares, maintained from previous assessments [7]. Core Insights - The company achieved a revenue of 14.095 billion RMB in 2025, representing a year-over-year increase of 14.8%, with adjusted non-IFRS net profit reaching 1.816 billion RMB, up 13.0% year-over-year. The performance aligns with the company's earnings forecast, showing a positive acceleration in overall performance [1]. - The company expects a revenue growth of 12%-18% in 2026, driven by a recovery in downstream industry demand and the strengthening of its core laboratory services [1]. - The gross margin for 2025 was 34.8%, an increase of 0.6 percentage points year-over-year, supported by improved performance in key business segments [2]. Summary by Sections Financial Performance - In 2025, the company reported a net cash flow from operating activities of 3.221 billion RMB, reflecting a 25.0% year-over-year improvement [2]. - The company’s expenses for sales, management, and R&D were 2.2%, 12.3%, and 4.1% respectively, with R&D investment being a focus for long-term competitive strength [2]. Laboratory Services - The laboratory services segment generated revenue of 8.159 billion RMB in 2025, a 15.8% increase year-over-year, with over 56% of this revenue coming from biological sciences [3]. - The company is enhancing its flagship business capabilities, expanding into complex new molecular synthesis while applying AI and automation technologies in laboratory chemistry [3]. Other Business Segments - The CMC segment achieved revenue of 3.483 billion RMB in 2025, up 16.5% year-over-year, with a gross margin of 34.3% [4]. - The clinical CRO segment reported revenue of 1.957 billion RMB, a 7.1% increase year-over-year, with expectations for continued positive growth in 2026 [4]. - The large molecule and CGT segment generated revenue of 475 million RMB, also reflecting a 16.5% year-over-year increase, indicating a strengthening of business capabilities [4]. Profit Forecast and Valuation - The company’s net profit forecasts for 2026-2028 are adjusted to 1.933 billion RMB, 2.273 billion RMB, and 2.694 billion RMB respectively, with a target price of 39.98 RMB for A shares and 31.02 HKD for H shares, based on a PE ratio of 38x for A shares and 26x for H shares [5].

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Views - The company's performance in the first half of 2025 met expectations, with revenue of 6.441 billion yuan (up 14.9% year-on-year) and adjusted non-IFRS net profit of 756 million yuan (up 9.5% year-on-year) [1]. - The overall growth momentum remains strong, supported by a continuous increase in customer inquiries and new order amounts, which grew by over 10% year-on-year in the first half of 2025 [1]. - The report anticipates a favorable development for the company in 2025, driven by a recovering industry demand and the solid capabilities of its laboratory services [1]. Summary by Sections Financial Performance - In the first half of 2025, the company's gross margin was 34.0% (up 0.6 percentage points year-on-year), with significant contributions from core businesses such as laboratory services and CMC [2]. - The operating cash flow for the first half of 2025 was 1.408 billion yuan (up 28.1% year-on-year), indicating a positive trend in cash flow [2]. Laboratory Services - Revenue from the laboratory services segment in the first half of 2025 was 3.892 billion yuan (up 15.5% year-on-year), with biological sciences accounting for over 55% of the segment's revenue [3]. - The segment participated in 795 drug discovery projects (up 19.4% year-on-year) and saw new order amounts increase by over 10% [3]. - The company is enhancing its core business capabilities and applying AI technology, with the second Beijing park gradually coming into operation in the first half of 2025 [3]. Other Businesses - CMC business revenue in the first half of 2025 was 1.390 billion yuan (up 18.2% year-on-year), with a gross margin of 30.5% (up 2.2 percentage points) [4]. - The clinical CRO segment generated revenue of 939 million yuan (up 11.4% year-on-year), with a quarter-on-quarter increase of 10.0% in the second quarter of 2025 [4]. - The large molecule and CGT segment reported revenue of 211 million yuan (up 0.1% year-on-year), with a quarter-on-quarter increase of 14.3% in the second quarter of 2025 [4]. Profit Forecast and Valuation - The profit forecast remains unchanged, with expected net profits for 2025-2027 at 1.728 billion, 2.103 billion, and 2.507 billion yuan respectively [5]. - The company is assigned a target price of 39.83 yuan for A shares and 28.54 HKD for H shares, reflecting a PE ratio of 41x for A shares and 27x for H shares in 2025 [5].